GAD 65 ANTIBODY PARANEOPLASTIC SYNDROME

The GAD 65 Antibody test detects antibodies directed against the 65 kDa isoform of glutamic acid decarboxylase (GAD65) in the blood, helping identify autoimmune and paraneoplastic neurological syndromes. Performed on a venous serum sample using validated immunoassays, the test aids clinicians in distinguishing immune-mediated neurological disorders such as stiff-person syndrome, limbic encephalitis, or cerebellar ataxia that may be associated with an underlying malignancy. Available with home collection across Dubai and the UAE, results are delivered quickly with expert laboratory interpretation to support timely diagnostic and oncology follow-up.

• GAD65 (Anti-Glutamic Acid Decarboxylase 65) Antibody (IgG)
• Antibody Titer (U/mL)
• Result Interpretation (Negative / Borderline / Positive)
• Reference Range / Cut-off Value

• Subacute or progressive cerebellar ataxia without clear cause
• Clinical features of stiff‑person syndrome or muscle rigidity
• New-onset seizures, limbic encephalitis, or unexplained cognitive decline
• Suspected paraneoplastic neurological syndrome in patients with known or suspected cancer
• Evaluation of autoimmune etiology in atypical or refractory neurological presentations

• Home blood collection across Dubai and the UAE for patient convenience
• Accurate, validated immunoassay with quantitative titer reporting
• Fast laboratory turnaround and secure result delivery
• Expert interpretation notes to guide neurology and oncology follow-up
• Supports early detection of paraneoplastic or autoimmune neurological causes

• At-home venous blood collection by a trained phlebotomist
• No fasting required (unless combined with other tests as advised)
• Provide relevant clinical history, current medications, and any cancer diagnosis
• Valid patient identification and informed consent for sample collection